Fimbrion Therapeutics is a cutting-edge brand specializing in the development of novel therapeutics to combat serious infections. With a mission to create powerful alternatives to traditional antibiotics, Fimbrion is at the forefront of innovation in the medical field. They offer a diverse pipeline of groundbreaking products, targeting a range of conditions including urinary tract infections (UTIs) and tuberculosis.

Recently, Fimbrion was awarded Phase II SBIR funding to further develop their revolutionary therapies for tuberculosis, highlighting their commitment to making a lasting impact on global health. Additionally, in collaboration with GSK, they have identified a novel, antibiotic-sparing development candidate for UTIs, providing hope for those suffering from recurrent infections. Fimbrion's leadership team is comprised of distinguished experts in the field, including individuals who have been recognized by prestigious organizations such as the National Academy of Inventors.

Their dedication to advancing medical science and finding new solutions is evident in their impressive portfolio of publications. To learn more about Fimbrion Therapeutics and their groundbreaking work, visit their website or get in touch with their passionate team